Zhang ZY, Xu HY, Chen B, Yang YJ, Zhang L, Wang M, Xu YC, Zhang FC. Influence of deep hyperthermia combined with systemic chemotherapy on overall survival of recurrent gastric cancer patients: Predictors of response to treatment.
Shijie Huaren Xiaohua Zazhi 2015;
23:438-444. [DOI:
10.11569/wcjd.v23.i3.438]
[Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/06/2023] Open
Abstract
AIM: To investigate the effect of tumor deep hyperthermia combined with systemic chemotherapy on overall survival (OS) of recurrent gastric cancer patients, and to explore the predictors of response to the treatment.
METHODS: Ninety-nine patients with recurrent gastric cancer were divided into either a thermo-chemotherapy group (n = 42) or a control group (n = 57). The thermo-chemotherapy group was treated by deep tumor hyperthermia and chemotherapy, and the control group received systemic chemotherapy alone. The OS was compared for the two groups, and the predictors of response to individualized treatment was analyzed.
RESULTS: The median OS was significantly longer in the thermo-chemotherapy group than in the control group (18 mo vs 12.8 mo. (P = 0.003). In the thermo-chemotherapy group, the OS of patients with albumin (ALB) ≥ 35 g/L (19 mo) was better than that of patients with ALB < 35g/L (10 mo) ((P = 0.027); and the OS of patients with a neutrophil/lymphocyte ratio (NLR) < 4.558 (33 mo) was superior than that of patients with an NLR ≥ 4.558 (10 mo) ((P = 0.007).
CONCLUSION: For recurrent gastric cancer patients, thermotherapy combined with chemotherapy may be a more effective treatment option. Patients with normal serum ALB and an NLR < 4.558 may have a better prognosis. For patients with ALB < 35 g/L and an NLR ≥ 4.558, deep tumor hyperthermia combined with systemic chemotherapy is not recommended.
Collapse